Program Description:
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and International Society on Thrombosis and Haemostasis. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit Statement:
The Medical College of Wisconsin designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Please note: The course fee is $10.00 in addition to a $2.50 processing fee which is assessed for all electronic registrations.
Target audience:
Basic and clinical scientists, including platelet biologists, vascular biologists and hematologists, interested in translational research
Learning objectives:
At the conclusion of this activity, I will be able to:
- Explain the role of polyphosphate in modulating blood clotting
- Distinguish between the procoagulant and proinflammatory actions of polyphosphate
- Explore the possibility of polyphosphate as a novel prohemostatic agent, and also as a possible antithrombotic drug target
Faculty & credentials:
Planning Committee:
Geoffrey Barnes, MD
Chris Ward, PhD
Stephen Watson, PhD
Yukio Ozaki
Speakers:
Part I: Platelet Polyphosphates in Hemostasis
James Morrissey, University of Illinois (USA)
Part II: Platelet Alpha-Granules in Hemostasis
Walter Kahr, University of Toronto (Canada)
Moderator: Stephanie Smith, University of Illinois (USA)
All persons in control of content have NO relevant financial relationships to disclose with the exception of the following persons:
Name | Company | Role |
Geoffrey Barnes, MD | Portola | Consulting |
Blue Cross Blue Shield of Michigan | Research | |
BMS/Pfizer | Research | |
Chris Ward, PhD | Bayer | Speaker |
Boehringer-Ingelheim | Speaker, Advisory Board | |
BMS/Pfizer | Speaker, Advisory Board | |
Yukio Ozaki | The Sysmex Corporation | Advisory Board |
James Morrissey | rEVO Biologics, Alnylam Pharmaceuticals, Novo Nordisk, Smartzyme, Diagnostica Stago, PrevThro, Inc. | Consultant, Inventor, Co-owner |
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.
Contact
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.